However, whether differences in the expression of LTF, ARG1, PGLYRP1, S100A12, and CAMP /LL-37 between AML and CML are reflected in differences in immunomodulatory effects and disease progression remains to be determined. This evidence concerns the gene LTF and chronic myelogenous leukemia, BCR-ABL1 positive.